Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Not yet recruiting · NCT07282197 · Registry updated 2025-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 2 | 2025-12-15 | NCT07282197 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University First Hospital | 225 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University First Hospital | Beijing | China | 72 |